|
|
|
Volumn 29, Issue 3, 2005, Pages 32-40
|
|
Combination products raise manufacturing challenges
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DRUG DOSAGE;
DRUG INFUSION;
DRUG PRODUCTS PLANTS;
DRUG THERAPY;
PRODUCT DEVELOPMENT;
REGULATORY COMPLIANCE;
COMBINATION PRODUCTS;
FIXED-DOSE COMBINATION;
MANUFACTURING CHALLENGES;
DRUG PRODUCTS;
ABACAVIR;
ABACAVIR PLUS LAMIVUDINE;
AMLODIPINE BESYLATE;
AMLODIPINE PLUS ATORVASTATIN;
ANTIRETROVIRUS AGENT;
ATORVASTATIN;
EFAVIRENZ;
EMTRICITABINE;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
LAMIVUDINE;
LAMIVUDINE PLUS ZIDOVUDINE;
NEVIRAPINE;
TENOFOVIR DISOPROXIL;
UNCLASSIFIED DRUG;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
DRUG BIOAVAILABILITY;
DRUG CAPSULE;
DRUG COST;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG LABELING;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG SAFETY;
DRUG SOLUBILITY;
DRUG STABILITY;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE POLICY;
HUMAN;
HYPERCHOLESTEROLEMIA;
HYPERTENSION;
MEDICATION ERROR;
ORGANIZATION;
PATIENT COMPLIANCE;
PHARMACOKINETICS;
PRACTICE GUIDELINE;
REVIEW;
RISK BENEFIT ANALYSIS;
STANDARD;
TABLET;
|
|
EID: 15244344076
PISSN: 15432521
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (4)
|
|
References (0)
|
